QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - NYSE:QGEN - NL0015002CX3 - Common Stock
45.68 USD
-1.17 (-2.5%)
45.67 USD
-0.01 (-0.02%)
Overall QGEN gets a fundamental rating of 6 out of 10. We evaluated QGEN against 58 industry peers in the Life Sciences Tools & Services industry. QGEN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. QGEN is not valued too expensively and it also shows a decent growth rate. With these ratings, QGEN could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year QGEN was profitable.
In the past year QGEN had a positive cash flow from operations.
Each year in the past 5 years QGEN has been profitable.
In the past 5 years QGEN always reported a positive cash flow from operatings.
1.2 Ratios
QGEN has a better Return On Assets (6.41%) than 84.48% of its industry peers.
The Return On Equity of QGEN (10.65%) is better than 82.76% of its industry peers.
QGEN has a better Return On Invested Capital (8.66%) than 82.76% of its industry peers.
The Average Return On Invested Capital over the past 3 years for QGEN is significantly below the industry average of 13.51%.
The 3 year average ROIC (7.25%) for QGEN is below the current ROIC(8.66%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.41% | ||
| ROE | 10.65% | ||
| ROIC | 8.66% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
QGEN's Profit Margin of 18.30% is amongst the best of the industry. QGEN outperforms 91.38% of its industry peers.
In the last couple of years the Profit Margin of QGEN has declined.
QGEN has a Operating Margin of 26.86%. This is amongst the best in the industry. QGEN outperforms 94.83% of its industry peers.
In the last couple of years the Operating Margin of QGEN has grown nicely.
The Gross Margin of QGEN (64.18%) is better than 86.21% of its industry peers.
In the last couple of years the Gross Margin of QGEN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.86% | ||
| PM (TTM) | 18.3% | ||
| GM | 64.18% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so QGEN is still creating some value.
The number of shares outstanding for QGEN has been reduced compared to 1 year ago.
QGEN has less shares outstanding than it did 5 years ago.
QGEN has a better debt/assets ratio than last year.
2.2 Solvency
QGEN has an Altman-Z score of 4.04. This indicates that QGEN is financially healthy and has little risk of bankruptcy at the moment.
QGEN has a Altman-Z score of 4.04. This is in the better half of the industry: QGEN outperforms 74.14% of its industry peers.
QGEN has a debt to FCF ratio of 2.91. This is a good value and a sign of high solvency as QGEN would need 2.91 years to pay back of all of its debts.
QGEN has a better Debt to FCF ratio (2.91) than 81.03% of its industry peers.
QGEN has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
QGEN has a Debt to Equity ratio (0.25) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 2.91 | ||
| Altman-Z | 4.04 |
ROIC/WACC1.15
WACC7.56%
2.3 Liquidity
A Current Ratio of 1.61 indicates that QGEN should not have too much problems paying its short term obligations.
QGEN has a worse Current ratio (1.61) than 63.79% of its industry peers.
QGEN has a Quick Ratio of 1.35. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of QGEN (1.35) is worse than 65.52% of its industry peers.
QGEN does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
QGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.20%, which is quite good.
The Earnings Per Share has been growing by 8.40% on average over the past years. This is quite good.
Looking at the last year, QGEN shows a small growth in Revenue. The Revenue has grown by 5.15% in the last year.
QGEN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.32% yearly.
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%
3.2 Future
QGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.78% yearly.
Based on estimates for the next years, QGEN will show a small growth in Revenue. The Revenue will grow by 7.82% on average per year.
EPS Next Y8.55%
EPS Next 2Y8.08%
EPS Next 3Y8.5%
EPS Next 5Y8.78%
Revenue Next Year5.25%
Revenue Next 2Y5.45%
Revenue Next 3Y5.86%
Revenue Next 5Y7.82%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.44, the valuation of QGEN can be described as rather expensive.
84.48% of the companies in the same industry are more expensive than QGEN, based on the Price/Earnings ratio.
QGEN is valuated rather cheaply when we compare the Price/Earnings ratio to 26.11, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 17.60, which indicates a rather expensive current valuation of QGEN.
86.21% of the companies in the same industry are more expensive than QGEN, based on the Price/Forward Earnings ratio.
QGEN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.55, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.44 | ||
| Fwd PE | 17.6 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 94.83% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, QGEN is valued cheaply inside the industry as 86.21% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.97 | ||
| EV/EBITDA | 14.15 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
QGEN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.27
PEG (5Y)2.31
EPS Next 2Y8.08%
EPS Next 3Y8.5%
5. Dividend
5.1 Amount
QGEN has a yearly dividend return of 0.54%, which is pretty low.
Compared to an average industry Dividend Yield of 0.50, QGEN pays a better dividend. On top of this QGEN pays more dividend than 91.38% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.37, QGEN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
5.2 History
QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y8.08%
EPS Next 3Y8.5%
45.68
-1.17 (-2.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.95%
Inst Owner Change-7.64%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap9.90B
Revenue(TTM)2.04B
Net Income(TTM)373.39M
Analysts74.17
Price Target52.09 (14.03%)
Short Float %2.82%
Short Ratio5.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.7%
Min EPS beat(2)-2.4%
Max EPS beat(2)7.8%
EPS beat(4)2
Avg EPS beat(4)1.23%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.51%
EPS beat(12)8
Avg EPS beat(12)3.69%
EPS beat(16)12
Avg EPS beat(16)5.44%
Revenue beat(2)1
Avg Revenue beat(2)0.66%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)1.43%
Revenue beat(4)1
Avg Revenue beat(4)-0.16%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.61%
Revenue beat(12)3
Avg Revenue beat(12)-0.41%
Revenue beat(16)7
Avg Revenue beat(16)0.85%
PT rev (1m)-1.37%
PT rev (3m)1.07%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)0.3%
EPS NY rev (1m)-0.05%
EPS NY rev (3m)0.7%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)1.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.44 | ||
| Fwd PE | 17.6 | ||
| P/S | 4.86 | ||
| P/FCF | 19.97 | ||
| P/OCF | 14.67 | ||
| P/B | 2.83 | ||
| P/tB | 15.49 | ||
| EV/EBITDA | 14.15 |
EPS(TTM)2.35
EY5.14%
EPS(NY)2.6
Fwd EY5.68%
FCF(TTM)2.29
FCFY5.01%
OCF(TTM)3.11
OCFY6.82%
SpS9.41
BVpS16.17
TBVpS2.95
PEG (NY)2.27
PEG (5Y)2.31
Graham Number29.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.41% | ||
| ROE | 10.65% | ||
| ROCE | 11.67% | ||
| ROIC | 8.66% | ||
| ROICexc | 10.87% | ||
| ROICexgc | 46.44% | ||
| OM | 26.86% | ||
| PM (TTM) | 18.3% | ||
| GM | 64.18% | ||
| FCFM | 24.31% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexgc growth 3Y-31.24%
ROICexgc growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 2.91 | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 94.78% | ||
| Cap/Sales | 8.78% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.61% | ||
| Profit Quality | 132.83% | ||
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 4.04 |
F-Score8
WACC7.56%
ROIC/WACC1.15
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
EPS Next Y8.55%
EPS Next 2Y8.08%
EPS Next 3Y8.5%
EPS Next 5Y8.78%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%
Revenue Next Year5.25%
Revenue Next 2Y5.45%
Revenue Next 3Y5.86%
Revenue Next 5Y7.82%
EBIT growth 1Y21.82%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.27%
EBIT Next 3Y22.23%
EBIT Next 5Y15.78%
FCF growth 1Y31.74%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y29.99%
OCF growth 3Y1.77%
OCF growth 5Y15.28%
QIAGEN N.V. / QGEN FAQ
Can you provide the ChartMill fundamental rating for QIAGEN N.V.?
ChartMill assigns a fundamental rating of 6 / 10 to QGEN.
What is the valuation status of QIAGEN N.V. (QGEN) stock?
ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.
What is the profitability of QGEN stock?
QIAGEN N.V. (QGEN) has a profitability rating of 8 / 10.
What are the PE and PB ratios of QIAGEN N.V. (QGEN) stock?
The Price/Earnings (PE) ratio for QIAGEN N.V. (QGEN) is 19.44 and the Price/Book (PB) ratio is 2.83.